MedStar Authors catalog › Details for: Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis.
Citation: European Heart Journal. 37(28):2252-62, 2016 Jul 21.Journal: European heart journal.Published: 2016ISSN: 0195-668X.Full author list: Kodali S; Thourani VH; White J; Malaisrie SC; Lim S; Greason KL; Williams M; Guerrero M; Eisenhauer AC; Kapadia S; Kereiakes DJ; Herrmann HC; Babaliaros V; Szeto WY; Hahn RT; Pibarot P; Weissman NJ; Leipsic J; Blanke P; Whisenant BK; Suri RM; Makkar RR; Ayele GM; Svensson LG; Webb JG; Mack MJ; Smith CR; Leon MB.UI/PMID: 27190101.Subject(s): Aortic Valve | *Aortic Valve Stenosis | Canada | Cardiac Catheterization | Echocardiography | Humans | Prospective Studies | Transcatheter Aortic Valve Replacement | Treatment OutcomeInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.1093/eurheartj/ehw112 (Click here)Abbreviated citation: Eur Heart J. 37(28):2252-62, 2016 Jul 21.Local Holdings: Available online from MWHC library: 1996 - present (after 1 year), Available in print through MWHC library: 1999 - 2006.Abstract: AIMS: Based on randomized trials using first-generation devices, transcatheter aortic valve replacement (TAVR) is well established in the treatment of high-risk (HR) patients with severe aortic stenosis (AS). To date, there is a paucity of adjudicated, prospective data evaluating outcomes with newer generation devices and in lower risk patients. We report early outcomes of a large, multicentre registry of inoperable, HR, and intermediate-risk (IR) patients undergoing treatment with the next-generation SAPIEN 3 transcatheter heart valve (THV).Abstract: METHODS AND RESULTS: Patients with severe, symptomatic AS (583 high surgical risk or inoperable and 1078 IR) were enrolled in a multicentre, non-randomized registry at 57 sites in the USA and Canada. All patients received TAVR with the SAPIEN 3 system via transfemoral (n = 1443, 86.9%) and transapical or transaortic (n = 218, 13.1%) access routes. The rate of 30-day all-cause mortality was 2.2% in HR/inoperable patients [mean Society of Thoracic Surgeons (STS) score 8.7%] and 1.1% in IR patients (mean STS score 5.3%); cardiovascular mortality was 1.4 and 0.9%, respectively. In HR/inoperable patients, the 30-day rate of major/disabling stroke was 0.9%, major bleeding 14.0%, major vascular complications 5.1%, and requirement for permanent pacemaker 13.3%. In IR patients, the 30-day rate of major/disabling stroke was 1.0%, major bleeding 10.6%, major vascular complications 6.1%, and requirement for permanent pacemaker 10.1%. Mean overall Kansas City Cardiomyopathy Questionnaire score increased from 47.8 to 67.8 (HR/inoperable, P < 0.0001) and 54.7 to 74.0 (IR, P < 0.0001). Overall, paravalvular regurgitation at 30 days was none/trace in 55.9% of patients, mild in 40.7%, moderate in 3.4%, and severe in 0.0%. Mean gradients among patients with paired baseline and 30-day or discharge echocardiograms decreased from 45.8 mmHg at baseline to 11.4 mmHg at 30 days, while aortic valve area increased from 0.69 to 1.67 cm(2).Abstract: CONCLUSIONS: The SAPIEN 3 THV system was associated with low rates of 30-day mortality and major/disabling stroke as well as low rates of moderate or severe paravalvular regurgitation.Abstract: TRIAL REGISTRATION: ClinicalTrials.gov #NCT01314313.Abstract: Copyright Published on behalf of the European Society of Cardiology. All rights reserved. (c) The Author 2016. For permissions please email: [email protected]